REFERENCES

Lukali V, Michelo C. Factors Associated with Irrational Drug use at a District Hospital in Zambia: Patient Record-based Observations. Medical Journal of Zambia. 2015; 42(1): 25-30. [View article](http://www.ajol.info/index.php/mjz/article/view/125814)

Awad AI, Ball DE, Eltayeb IB. Improving irrational drug use in Africa: the example of Sudan. The East Mediterranean Journal. 2007; 13(5): 1202-1211. [View abstract](http://www.ncbi.nlm.nih.gov/pubmed/18290415)

Abdella S. and Wade N. (2012). Prescribers adherence to the basic principles of prescription orders writing in South West Ethiopia. Natl J Physiol Pharm Pharmacol

Stoppacher, R. and Adams, S.P., 2003. Malaria deaths in the United States: case report and review of deaths, 1979-1998. *Journal of forensic sciences*, *48*(2), pp.404-408.

Mohajan, H.K., 2015. Tuberculosis is a fatal disease among some developing countries of the world. *American Journal of Infectious Diseases and Microbiology*, *3*(1), pp.18-31.

White, F., 2015. Primary health care and public health: foundations of universal health systems. *Medical Principles and Practice*, *24*(2), pp.103-116.

Cameron, A., Ewen, M., Auton, M. and Abegunde, D., 2011. The world medicines situation 2011. *Medicine prices, availability and affordability.[http://www. who. int/medicines/areas/policy/world\_medicines\_situation/WMS\_ch6\_wPricing\_v6. pdf]*.

De Vries, T.P.G., Henning, R.H., Hogerzeil, H.V., Fresle, D.A., Policy, M. and World Health Organization, 1994. Guide to good prescribing: a practical manual.

Harris, J., 2012. Assessing the rational use of essential medicines in public health facilities Montserrado County, Liberia

Ambwani, S., & Mathur, A. K. (2006). CHAPTER–2 RATIONAL DRUG USE. *Health administrator*, *19*(1), 5-7.

MSH, 2012. Managing access to medicines and health technology accessed on [www.msd-online.org](http://www.msd-online.org)

Goudge, J., Gilson, L., Russell, S., Gumede, T. and Mills, A., 2009. Affordability, availability and acceptability barriers to health care for the chronically ill: longitudinal case studies from South Africa. *BMC health services research*, *9*(1), p.75.

Hayford, K., Privor-Dumm, L. and Levine, O., 2011. Improving access to essential medicines through public-private partnerships. *Baltimore2011*.

Hagnour B., 2014 Factors responsible for irrational prescribing. Sudan Journal of irrational use of medicines

Strategy, W.M., 2004. Countries at the core. *World Health Organization*.

WHO 2008. More drugs for more developing world

Wellems, T.E. and Plowe, C.V., 2001. Chloroquine-resistant malaria. *Journal of Infectious Diseases*, *184*(6), pp.770-776.

Hutin, Y. et al. Best injection practices for intradermal, subcutaneous and intramuscular

needle injection. Bulletin of World Health Organization (WHO), 2003;81: 491

-

500

WHO 2003. Access to medicines in low-income countries (Chapter 15)

Laing, R., Waning, B., Gray, A., Ford, N. and Hoen, E.T., 2003. 25 years of the WHO essential medicines lists: progress and challenges. *The Lancet*, *361*(9370), pp.1723-1729.

(WHO, n.d) Access to affordable medicines

Santos M., 2016. Access to essential medicines. Medical Journal Association

World Health Organization, Health reform and drug financing, Selected topics, Health economics and drugs, DAP series no. 6, WHO/DAP/98.3, World Health Organization, Geneva, Switzerland, 1998

Landecker, H., 2016. Antibiotic resistance and the biology of history. *Body & Society*, *22*(4), pp.19-52.

Mao, W., Vu, H., Xie, Z., Chen, W. and Tang, S., 2015. Systematic review on irrational use of medicines in China and Vietnam. *PloS one*, *10*(3), p.e0117710.

Aronson, J.K., 2006. Balanced prescribing. *British journal of clinical pharmacology*, *62*(6), pp.629-632.

WHO 2010, Rational Use of Medicines, Fact Sheet N\*338 May 2010 available from <http://www.who.int/mediacentre/factsheets/fs338/en>, accessed on 10 March 2017

WHO 2003. Drug and Therapeutic Committees- a practical Guide

Oboh, L., 2013. A pill for every ill: the dangers of polypharmacy in older people. *Nursing And Residential Care*, *15*(10), pp.666-669.

Gayle, H.D. and Hill, G.L., 2001. Global impact of human immunodeficiency virus and AIDS. *Clinical microbiology reviews*, *14*(2), pp.327-335.

*.(Celik E., Sencan M, Clark M., 2013. Factors affecting rational drug use (RDU) Compliance and wastage. Turkish J Pharm. Sci. 10(1)*

*Awad A., Eltayb I., Matowel, Thalib L., 2005. Self medication with antibiotics and antimalarials in the community of Khartoum state, Sudan.available from* [*www.ualberta.ca/-csps/JPPS8(2)/A.Awad/sudan .htm*](http://www.ualberta.ca/-csps/JPPS8%282%29/A.Awad/sudan%20.htm)*, accessed on 10 March 2017*

*MOH and DGoP, 2007. Assessment of national Pharmaceutical Sector North Sudan*

Mao, W., Vu, H., Xie, Z., Chen W. and Tand, S.., 2015. Systematic review on irrational use of medicines in China and Vietnam. PloS one, 10(3), p.e0117710.

United Nations Development Group, *Indicators for Monitoring the Millennium Development*

*Goals* (United Nations, New York, 2003).

Hogerzeil H., Ways of improving access to essential medicines in developing countries The Pharmaceutical Journal Vol 269 No 7215 p372-373 [14 September 2002](http://www.pharmaceutical-journal.com/ContentsPages/Contents20020914.html)

Irrational prescribing of over-the-counter (OTC) medicines in general practice: testing the feasibility of an educational intervention among physicians in five European countries

Mao, W., Vu, H., Xie, Z., Chen, W. and Tang, S., 2015. Systematic review on irrational use of medicines in China and Vietnam. *PloS one*, *10*(3), p.e0117710.

Bhargava A., and Kalantri 2013 The crisis in access to medicines in India. Key issues which call for action. Indian Journal of Medical Ethics Vol x No 2

 Hogerzeil H (1995) Promoting rational drug use: an international perspective. Brit J Clin Pharmaco 39:1–6.

 White TJ, Araekelian A, Rho JP (1999) Counting the costs of drug related adverse events. Pharmacoeconomics, 15(5):445–458.

Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. Journal of the American Medical Association 279(15):120–125.

 Hitchen L (2006) Adverse drug reactions result in 250 000 UK admissions a year. Brit Med J 332:1109.

Pirmohamed M, James S, Meakin S, Green C, Scott AK, et al. (2004) Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18,820 patients. Brit Med J 329:15–19.

Ng, R. (2008). Appendix 1: History of Drug Discovery and Development. *Drugs: From Discovery to Approval, Second Edition*, 391-397.

WHO 2016. Universal Health Coverage Factsheet

WHO: How to investigate drug use in health facilities: selected drug use indicators. Geneva:WHO/DAP/93.1; 1993. <http://www.who.int/medicinedocs/en/d/Js2289e/> Accessed May 2017

Bilal, A.I., Osman, E.D. and Mulugeta, A., 2016. Assessment of medicines use pattern using World Health Organization’s Prescribing, Patient Care and Health facility indicators in selected health facilities in eastern Ethiopia. *BMC health services research*, *16*(1), p.144.

Bannenberg WJ, Forshaw CJ, Fresle D, Salami AO, Wahab HA: Evaluation of the Nile province essential drug project. WHO: Geneva; 1991. WHO/DAP/91.10. In: How to investigate drug use in health facilities. Geneva, WHO, 1993: 74 (WHO/DAP/93.1). <https://extranet.who.int/iris/restricted/handle/10665/63301>. Accessed Sept 2015.

Ministry of Health/Zimbabwe Essential Drugs Action Programme: Essential Drugs Survey. In How to investigate drug use in health facilities. WHO: Geneva; 1993. 74(WHO/DAP/93.1).

Desalegn A. Assessment of drug use pattern using WHO prescribing indicators at Hawassa University teaching and referral hospital, south Ethiopia: a cross-sectional study. BMC Health Serv Res. 2013;13:170.

Bimo: Report on Nigerian field test. INRUD News 1992; 3(1): 9–10. In How to investigate drug use in health facilities. Geneva: WHO; 1993. 74(WHO/DAP/93.1).

Christensen RF: A strategy for the improvement of prescribing and drug use in rural health facilities in Uganda. Ugandan Essential drugs and management program; 2 September-11 October 1990. In how to investigate drug use in health facilities. Geneva: WHO; 1993.74(WHO/DAP/93.1).[http://apps.who.int/medicinedocs/en/d/Js2289e/8.3.html. Accessed 24 Feb 2014](http://apps.who.int/medicinedocs/en/d/Js2289e/8.3.html.%20Accessed%2024%20Feb%202014).

Etefa W, Teshale C, Hawaze S. Assessment of dispensing practice in South West Ethiopia: the case of Jimma university specialized Hospital. Int J Pharm. 2013;3:668–74.

Massele AY, Nsimba SE, Rimoy G. Prescribing habits in church-owned primary health care facilities in Dar Es Salaam and other Tanzanian coast regions. East Afr Med J. 2001;78:510–4.

K. Holloway, T. Green, and World Health Organization, “Drug and therapeutics committees: a -practical guide”.

[Christos Lionis](https://www.ncbi.nlm.nih.gov/pubmed/?term=Lionis%20C%5BAuthor%5D&cauthor=true&cauthor_uid=24533792),1 [Elena Petelos](https://www.ncbi.nlm.nih.gov/pubmed/?term=Petelos%20E%5BAuthor%5D&cauthor=true&cauthor_uid=24533792),1 [Sue Shea](https://www.ncbi.nlm.nih.gov/pubmed/?term=Shea%20S%5BAuthor%5D&cauthor=true&cauthor_uid=24533792),1 [Georgia Bagiartaki](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bagiartaki%20G%5BAuthor%5D&cauthor=true&cauthor_uid=24533792),1 [Ioanna G Tsiligianni](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tsiligianni%20IG%5BAuthor%5D&cauthor=true&cauthor_uid=24533792),1 [Apostolos Kamekis](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kamekis%20A%5BAuthor%5D&cauthor=true&cauthor_uid=24533792),1 [Vasiliki Tsiantou](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tsiantou%20V%5BAuthor%5D&cauthor=true&cauthor_uid=24533792),2 [Maria Papadakaki](https://www.ncbi.nlm.nih.gov/pubmed/?term=Papadakaki%20M%5BAuthor%5D&cauthor=true&cauthor_uid=24533792),1 [Athina Tatsioni](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tatsioni%20A%5BAuthor%5D&cauthor=true&cauthor_uid=24533792),3 [Joanna Moschandreas](https://www.ncbi.nlm.nih.gov/pubmed/?term=Moschandreas%20J%5BAuthor%5D&cauthor=true&cauthor_uid=24533792),4 [Aristoula Saridaki](https://www.ncbi.nlm.nih.gov/pubmed/?term=Saridaki%20A%5BAuthor%5D&cauthor=true&cauthor_uid=24533792),1 [Antonios Bertsias](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bertsias%20A%5BAuthor%5D&cauthor=true&cauthor_uid=24533792),1,4 [Tomas Faresjö](https://www.ncbi.nlm.nih.gov/pubmed/?term=Faresj%26%23x000f6%3B%20T%5BAuthor%5D&cauthor=true&cauthor_uid=24533792),5 [Åshild Faresjö](https://www.ncbi.nlm.nih.gov/pubmed/?term=Faresj%26%23x000f6%3B%20%26%23x000c5%3B%5BAuthor%5D&cauthor=true&cauthor_uid=24533792),5 [Luc Martinez](https://www.ncbi.nlm.nih.gov/pubmed/?term=Martinez%20L%5BAuthor%5D&cauthor=true&cauthor_uid=24533792),6,12 [Dominic Agius](https://www.ncbi.nlm.nih.gov/pubmed/?term=Agius%20D%5BAuthor%5D&cauthor=true&cauthor_uid=24533792),7 [Yesim Uncu](https://www.ncbi.nlm.nih.gov/pubmed/?term=Uncu%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=24533792),8 [George Samoutis](https://www.ncbi.nlm.nih.gov/pubmed/?term=Samoutis%20G%5BAuthor%5D&cauthor=true&cauthor_uid=24533792),9 [Jiri Vlcek](https://www.ncbi.nlm.nih.gov/pubmed/?term=Vlcek%20J%5BAuthor%5D&cauthor=true&cauthor_uid=24533792),10 [Abobakr Abasaeed](https://www.ncbi.nlm.nih.gov/pubmed/?term=Abasaeed%20A%5BAuthor%5D&cauthor=true&cauthor_uid=24533792),10 and [Bodossakis Merkouris](https://www.ncbi.nlm.nih.gov/pubmed/?term=Merkouris%20B%5BAuthor%5D&cauthor=true&cauthor_uid=24533792)11

World Health Organization, 2002. Promoting rational use of medicines: core components.